Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12F0M | ISIN: CA80600L1094 | Ticker-Symbol: 0E6
München
22.01.25
08:00 Uhr
0,017 Euro
0,000
0,00 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
SCANDIUM INTERNATIONAL MINING CORP Chart 1 Jahr
5-Tage-Chart
SCANDIUM INTERNATIONAL MINING CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0120,02022.01.
GlobeNewswire (Europe)
12 Leser
Artikel bewerten:
(0)

Scandium International Mining Corp.: Scandium International Mining Announces TSX-V Listing And Voluntary Delisting From Tsx

Finanznachrichten News

RENO, Nev., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scandium International Mining Corp. (TSX:SCY and OTCBB: SCYYF) ("Scandium International" or the "Company"), a company focused on the development of its Nyngan Scandium project in New South Wales, Australia, today announces that it has received conditional approval to list its common shares on the TSX Venture Exchange (the "TSXV"). In connection with the TSXV listing, the Company will voluntarily delist its common shares from the Toronto Stock Exchange (the "TSX").

The Company's management and Board of Directors have determined that this transition is in the best interests of Scandium International. In arriving at this determination, the Company considered, among other things, the costs associated with a TSX listing versus a TSXV listing, its ability to continue to meet the continued listing requirements of the TSX in the future, its current market capitalization, the rules related to private placements and other forms of financing available to TSXV-listed issuers and the general suitability of a TSX listing versus a TSXV listing for an issuer with the Company's current profile and focus on the development of a mineral property.

"This shift to the TSXV allows Scandium International to focus on development of our Nyngan Scandium project and further exploration potential of our Honeybugle license." said CEO Peter Evensen.

The Company expects to delist its common shares from the TSX on or about January 31, 2025, and list its common shares on the TSXV on or about February 4, 2025. The Company will remain a "reporting issuer" under applicable Canadian securities laws through the listing transition process. The Company will retain the trading symbol "SCY" once listed on the TSXV, and its shares will continue to be quoted on the OTCQB under the symbol "SCYYF". Shareholder approval is not required under the policies of the TSX to proceed with the transition as the TSXV is an acceptable alternative market. No action is required by shareholders in connection with the transition of the Company's listing to the TSXV.

For inquiries to Scandium International Mining Corp, please contact:

Peter Evensen (CEO)
Tel: (775) 355-9500

Harry de Jonge (Comptroller)
Tel: (702) 703-0178

Email: ir@scandiummining.com

Cautionary Note Regarding Forward-Looking Information
This news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, including, without limitation, statements with respect to listing of the Company's common shares on the TSXV and delisting of the Company's common shares from the TSX, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.

For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.